Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05799313 · ClinicalTrials.gov registry record · NA
Home Versus Office Removal of Percutaneous Nerve Evaluation (PNE) Lead
A NA study of Overactive Bladder, sponsored by The Cleveland Clinic.
- Recruiting
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT05799313: Recruiting NA study of Overactive Bladder, sponsored by The Cleveland Clinic.
NCT05799313 is a NA study of Overactive Bladder that is actively recruiting participants, run by The Cleveland Clinic. The registered enrollment target is 30 participants, below the 207-participant average among 46 other Overactive Bladder trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05799313, a NA study of Overactive Bladder, is actively recruiting participants, sponsored by The Cleveland Clinic.
- RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
For women undergoing percutaneous nerve evaluation (PNE) for the treatment of overactive bladder the first step is the PNE interstim therapy trial. If the PNE works, patients may opt to have the interstim procedure. The purpose of this study is to see if patients who remove their PNE lead at home have the same satisfaction with the PNE trial as those women who have their lead removed in the office.
Primary Outcome
Patient reported satisfaction on a scale of 0 (not satisfied) to 10 (most satisfied)
Conditions Studied
Interventions
- OTHER At home removal
- OTHER In office removal
Study Locations (1)
Ohio
- Cleveland Clinic - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-06-07 |
| Est. Completion | 2026-12-31 |
| Phase | NA |
What NCT05799313 shows while recruiting
NCT05799313 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 207-participant average among 46 other Overactive Bladder trials with a reported enrollment target (86% lower).
The record links to 1 condition, with Overactive Bladder appearing as the primary indexed condition, and to 2 interventions - of which At home removal is the first listed.
NCT05799313 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT05799313 about?
NCT05799313 is a clinical study titled "Home Versus Office Removal of Percutaneous Nerve Evaluation (PNE) Lead". For women undergoing percutaneous nerve evaluation (PNE) for the treatment of overactive bladder the first step is the PNE interstim therapy trial. If the PNE works, patients may opt to have the interstim procedure. The purpose of this study is to see if patients who remove their PNE lead at home ha...
What is the current status of trial NCT05799313?
This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2023-06-07. Estimated completion is 2026-12-31.
What conditions does trial NCT05799313 study?
This clinical trial studies the following conditions: Overactive Bladder.
What interventions are being tested in trial NCT05799313?
The interventions under investigation include: At home removal (OTHER), In office removal (OTHER).
Who is sponsoring clinical trial NCT05799313?
This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05799313 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Overactive Bladder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05799313's enrollment target sits among peer trials
30 36th of 46 higher than 11 of 46 other Overactive Bladder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Overactive Bladder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Percutaneous Nerve Evaluation Trial Time
RECRUITING · NA
-
Sacral Neuromodulation for Male Overactive Bladder (MOAB)
RECRUITING · NA
-
Neuromodulating Cortical Regions Involved in Neurogenic Bladder in MS
RECRUITING · NA
-
A Real World Study of eCoin for Urgency Urinary Incontinence: Post Approval Evaluation (RECIPE)
RECRUITING · NA
-
At-Home Transcutaneous Tibial Nerve Stimulation for Overactive Bladder in Rural Women
RECRUITING · NA
-
Pelvic Health Electrically Evoked Recording (PEER) 2 Study
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI